Calcium antagonists for acute ischemic stroke
Related Experiment Video
Updated: Oct 16, 2026
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
1Dept of Neurology, Academical Medical Center, Meibergdreef 9, Amsterdam, Netherlands, 1105 AZ. jhorn@wxs.nl
Insights
Calcium antagonists do not reduce death or dependency after acute ischemic stroke. Evidence does not support their use in acute ischemic stroke patients.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Ischemic stroke involves a sudden loss of blood supply, leading to increased calcium ions in neurons.
- Inhibiting this calcium influx is hypothesized to protect neurons and reduce stroke-related disability.
Purpose of the Study:
- To evaluate the efficacy of calcium antagonists in reducing death or dependency following acute ischemic stroke.
- To investigate the impact of drug type, dosage, administration route, and timing on stroke outcomes.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) identified from a specialized register (searched March 1999).
- Inclusion criteria: RCTs comparing calcium antagonists with control in acute ischemic stroke patients.
- Data extraction and analysis focused on poor outcome (death or dependency), with intention-to-treat analyses where possible.
Main Results:
- 28 trials with 7521 patients were included. No significant effect of calcium antagonists on poor outcome or death was observed.
- Intravenous administration was linked to worse outcomes compared to oral routes.
- Higher doses of nimodipine and administration within 12 hours showed no benefit and were associated with poorer outcomes.
Conclusions:
- Current evidence does not support the use of calcium antagonists for patients experiencing acute ischemic stroke.
- Further research may be needed to clarify specific roles, if any, for these agents.
Background:
The sudden loss of blood supply in ischemic stroke is associated with increased levels of calcium ions within neurones. Inhibiting this increase could protect neurones and is thought to reduce neurological impairment, disability and handicap after stroke.
Objectives:
The aim of this review is to determine whether calcium antagonists reduce the risk of death or dependency after acute ischemic stroke. The influence of different drugs, dosages, routes of administration, time intervals after stroke and trial design on the risk of poor outcome was investigated.
Search Strategy:
Relevant trials were identified in the Specialised Register of Controlled Trials (last searched: March 1999).
Selection Criteria:
All truly randomised trials comparing a calcium antagonist with control in patients with acute ischaemic stroke were included.
Data Collection And Analysis:
Two authors assessed all trials and extracted the data. Poor outcome, defined as death or dependency in activities of daily living, was used as the main outcome. Analyses were, if possible, "intention-to-treat".
Main Results:
46 trials were identified of which 28 were included (7521 patients). No effect of calcium antagonists on poor outcome at the end of follow-up (OR 1.07, 95% CI 0.97/1.18), or on death at end of follow-up (OR 1.10, 95% CI 0.98/1.24) was found. Intravenous administration (i.v.) of calcium antagonists was associated with an increase in the number of patients with poor outcome compared to oral administration (indirect comparisons). Comparisons of different doses of nimodipine suggested that the highest doses were associated with poorer outcome. Administration within 12 hours of onset was associated with an increase in the proportion of patients with poor outcome, but this effect was largely due to the poor results associated with i.v. administration. A subgroup analysis on nimodipine (oral, 120 mg/day) started within 12 hours of stroke onset, did not show a beneficial effect.
Reviewer'S Conclusions:
No evidence is available to justify the use of calcium antagonists in patients with acute ischaemic stroke.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:15Ischemic Stroke l: Introduction
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...